p300 in Cardiac Development and Accelerated Cardiac Aging

Area of Science:

• Cardiovascular Biology
• Epigenetics
• Developmental Biology

Background:

• Heart disease is the leading global cause of death, linked to congenital defects and acquired adult dysfunctions.
• Epigenetics, particularly the role of Acetyltransferase p300 (p300), is critical in embryonic heart development and adult heart disease.
• Stress-induced pathways accelerate cardiac aging, leading to pathologies like hypertrophy, cardiomyopathy, and heart failure.

Purpose of the Study:

• To elucidate the role of Acetyltransferase p300 (p300) in embryonic heart development and adult cardiac pathologies.
• To investigate the epigenetic mechanisms by which p300 regulates cardiac gene expression.
• To explore the therapeutic potential of targeting p300 for preventing or treating accelerated cardiac aging and heart failure.

Main Methods:

• Examined the impact of p300 deficiency/abnormal expression on embryonic heart and neural tube development.
• Analyzed p300's role in epigenetic control of cardiac gene expression in adult hearts.
• Investigated p300 deregulation in response to hypertrophic and fibrogenic stress signals.
• Reviewed preclinical studies on pharmacologic or genetic normalization of p300 activity.

Main Results:

• p300 is essential for embryonic heart development; its deficiency causes embryonic lethality due to cardiac and neural tube deformities.
• p300 controls cardiac development via histone acetylation-mediated chromatin remodeling and transcriptional regulation.
• In adult hearts, p300 is differentially expressed and epigenetically regulates cardiac genes.
• Deregulation of p300 is linked to cardiac hypertrophy and fibrosis, common in aging-related heart conditions.
• Preclinical studies show normalizing p300 activity can prevent or halt cardiac aging pathologies.

Conclusions:

• Acetyltransferase p300 (p300) is a pivotal epigenetic regulator in both embryonic heart development and adult cardiac health.
• Dysregulation of p300 contributes to stress-induced cardiac aging, hypertrophy, and fibrosis.
• Targeting p300 with small molecule inhibitors presents a promising therapeutic strategy to combat accelerated cardiac aging and reduce heart disease mortality.